Studies how anti-PD1 melanoma treatment affects atypical moles
Follows adults with past melanoma and atypical moles during anti-PD1 adjuvant immunotherapy.
Key facts
- Who runs it
- John Kirkwood
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 20 Feb 2025
- Expected to end
- May 2029
- Type of study
- Observational
- Treatments tested
- Single agent, adjuvant anti-PD1 therapy
- Record updated
- 26 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a past melanoma and at least two atypical moles. They must be set to get anti-PD1 treatment after surgery.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Documented melanoma, with at least two atypical nevi of 4 mm diameter or more. The study title lists stages IIB to IIIC.
- Earlier treatment
- Must be set to receive single agent anti-PD1 therapy as adjuvant treatment. Must not have had anti-PD1 therapy before.
Main reasons for not taking part
- Earlier anti-PD1 therapy
- Strong immune suppression or active autoimmune disease needing immunosuppressive therapy
- Other active cancers that are not melanoma
- Currently receiving other anti-cancer therapy
- Other illnesses that rule out anti-PD1 therapy
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Subjects must have at least two atypical nevi of ≥ 4 mm diameter
- Subjects must have a current documented history of melanoma
- Subject must be ≥ 18 years and if female of childbearing potential, must agree to practice effective contraception per institutional SOC if sexually active
- Subjects will have been deemed candidates for adjuvant therapy with single agent anti-PD1 therapy
- Subjects must give written informed consent to participate in this study with consent signed and dated prior to entry into trial
Who cannot take part
- Patients who have previously received anti-PD1 therapy
- Patients who are receiving other anti-neoplastic therapy
- Patients with non-malignant diseases or indications that would preclude the administration of anti-PD1 therapy such as significant immune suppression or active autoimmune disease requiring disease modifying, immunosuppressive therapy, will be ineligible
- Patients with history of other active, non-melanoma cancers
Where in United States
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Danielle L Bednarz, RNTaking people
About the trial
What the trial wants to find out
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.
The group in the trial
- Patients Treated with single agent, adjuvant anti-PD1 therapy
Patients receiving single agent, adjuvant anti-PD1 therapy (given either as standard of care or as part of a separate investigational study)
Treatment: Single agent, adjuvant anti-PD1 therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical/Dysplastic Nevi in Patients With Stage IIB-IIIC Melanoma
- Plain-language title
- Studies how anti-PD1 melanoma treatment affects atypical molesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 January 2026